• About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Media Library
    • Philogen in the news
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • Webinars
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Sustainability (ESG)
Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Philogen in the news
    • Media Library
  • Work with us
    • Careers
    • Partnering

Il Consiglio di Amministrazione approva il progetto di bilancio di esercizio e il bilancio consolidato al 31 dicembre 2025 (Price sensitive)

Mar 27, 2026 | 2026, Investors, Press Releases

more details

The Board of Directors approves the draft financial statements and the consolidated financial statements as of december 31st, 2025 (courtesy translation) (Price sensitive)

Mar 27, 2026 | 2026, Investors, Press Releases

more details

2026 Swiss Chemical Society (SCS) Industrial Science Award for Samuele Cazzamalli, Head of Research at Philochem

Nov 28, 2025 | 2025, Press Releases, Scientific

Dr. Samuele Cazzamalli, Head of Research at Philochem, will be awarded the Industrial Science Award 2026 from the Swiss Chemical Society. His research has focused on the discovery of novel tumor-targeting diagnostic and therapeutic agents through the use of...

The Board of Directors approves the financial position for the third quarter of 2025

Nov 11, 2025 | 2025, Investors, Press Releases

more details

Il Consiglio di Amministrazione approva la Posizione Finanziaria Netta relativa al terzo trimestre 2025

Nov 11, 2025 | 2025, Investors, Press Releases

more details

Il Consiglio di Amministrazione Approva la Relazione Finanziaria Semestrale al 30 giugno 2025 (Price sensitive)

Sep 23, 2025 | 2025, Investors, Press Releases

more details
« Older Entries
Next Entries »

Recent Posts

  • Deposito del Verbale dell’Assemblea degli Azionisti
  • Il Consiglio di Amministrazione approva la posizione finanziaria netta relativa al Primo Trimestre 2026
  • The Board of Directors approves the financial position for the first quarter of 2026 (Courtesy English Translation)
  • Philogen to attend the 74th American Society Mass Spectrometry annual conference in San Diego, May 31 – June 4 2026
  • Philogen to attend the Society of Nuclear Medicine and Molecular Imaging (SNMM) annual meeting on May 30 – June 2, 2026

Recent Comments

    Legal

    Privacy Policy

    Privacy Policy / Cookie Policy

      Contacts

    • Follow
    • Follow

    Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it